Profile data is unavailable for this security.
About the company
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
- Revenue in USD (TTM)1.02bn
- Net income in USD44.99m
- Incorporated2009
- Employees705.00
- LocationApellis Pharmaceuticals Inc100 Fifth AvenueWALTHAM 02451United StatesUSA
- Phone+1 (617) 977-5700
- Fax+1 (916) 443-1908
- Websitehttps://apellis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.10bn | 246.00 | 11.47 | 2.51 | 10.01 | 2.54 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Organon & Co | 6.30bn | 501.00m | 2.11bn | 10.00k | 4.21 | 2.32 | 2.50 | 0.3342 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 248.52m | -278.00k | 2.12bn | 188.00 | -- | 21.38 | 623.93 | 8.53 | -0.0055 | -0.0055 | 2.53 | 1.01 | 1.39 | 1.11 | 6.25 | 1,321,899.00 | -0.1554 | -42.00 | -0.2203 | -50.53 | 91.09 | -- | -0.1119 | -194.15 | 2.37 | -0.5126 | 0.2618 | -- | 504.79 | 23.35 | 69.53 | -- | -- | -- |
| Ultragenyx Pharmaceutical Inc | 630.60m | -579.83m | 2.30bn | 1.29k | -- | 250.50 | -- | 3.64 | -5.94 | -5.94 | 6.46 | 0.095 | 0.4622 | 2.02 | 6.13 | 487,324.60 | -42.50 | -33.04 | -55.49 | -38.84 | 84.69 | 91.29 | -91.95 | -127.45 | 1.74 | -17.52 | 0.9809 | -- | 29.01 | 40.12 | 6.17 | -- | -4.24 | -- |
| Tarsus Pharmaceuticals Inc | 366.10m | -81.16m | 2.63bn | 323.00 | -- | 7.85 | -- | 7.19 | -2.01 | -2.01 | 8.99 | 7.89 | 0.8039 | 7.39 | 7.19 | 1,133,437.00 | -17.82 | -33.35 | -22.30 | -37.21 | 93.26 | -- | -22.17 | -125.04 | 4.25 | -- | 0.1774 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Supernus Pharmaceuticals Inc | 681.54m | -19.12m | 2.83bn | 674.00 | -- | 2.69 | 42.70 | 4.15 | -0.3408 | -0.3408 | 12.09 | 18.38 | 0.4934 | 0.959 | 4.30 | 1,011,185.00 | -1.38 | 4.25 | -1.79 | 5.58 | 89.91 | 87.90 | -2.80 | 10.41 | 1.56 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
| Apellis Pharmaceuticals Inc | 1.02bn | 44.99m | 2.85bn | 705.00 | 75.97 | 7.11 | 61.17 | 2.81 | 0.297 | 0.297 | 8.03 | 3.17 | 1.04 | 0.9298 | 3.25 | 1,441,698.00 | 4.59 | -61.31 | 6.04 | -76.53 | 88.85 | 86.49 | 4.43 | -157.26 | 3.10 | 2.51 | 0.5313 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 2.89bn | 979.00 | -- | 6.33 | -- | 7.38 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Catalyst Pharmaceuticals Inc | 578.20m | 217.56m | 2.94bn | 181.00 | 13.95 | 3.20 | 11.51 | 5.08 | 1.71 | 1.71 | 4.55 | 7.47 | 0.6341 | 3.45 | 7.02 | 3,194,453.00 | 23.86 | 24.62 | 27.38 | 28.82 | 85.68 | 85.77 | 37.63 | 31.73 | 6.40 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 200.84m | 3.15bn | 600.00 | 16.26 | 1.73 | 13.69 | 2.84 | 4.03 | 4.03 | 22.30 | 37.95 | 0.3286 | 3.09 | 6.13 | 1,850,798.00 | 5.94 | 4.13 | 6.16 | 4.30 | 56.10 | 56.31 | 18.09 | 13.13 | 2.51 | 8.11 | 0.3574 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Arcutis Biotherapeutics Inc | 317.93m | -44.32m | 3.19bn | 342.00 | -- | 19.84 | -- | 10.04 | -0.3545 | -0.3545 | 2.49 | 1.31 | 0.7866 | 1.75 | 3.63 | 929,616.90 | -10.97 | -61.20 | -16.53 | -68.48 | 89.96 | -- | -13.94 | -406.29 | 3.28 | -2.61 | 0.407 | -- | 229.74 | -- | 46.58 | -- | 77.12 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 597.97m | 35.92m | 3.23bn | 315.00 | 94.96 | 6.00 | 86.28 | 5.40 | 0.4484 | 0.4484 | 7.81 | 7.10 | 0.9435 | 2.13 | 15.61 | 1,898,327.00 | 5.67 | -8.31 | 6.85 | -9.52 | 87.52 | -- | 6.01 | -17.33 | 3.51 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Liquidia Corp | 69.22m | -121.85m | 3.62bn | 157.00 | -- | 163.62 | -- | 52.24 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
Data as of Feb 06 2026. Currency figures normalised to Apellis Pharmaceuticals Inc's reporting currency: US Dollar USD
59.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Oct 2025 | 13.75m | 10.89% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 12.22m | 9.68% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 9.90m | 7.84% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 9.32m | 7.38% |
| Deep Track Capital LPas of 30 Sep 2025 | 8.00m | 6.34% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 5.34m | 4.23% |
| AQR Capital Management LLCas of 30 Sep 2025 | 4.49m | 3.55% |
| UBS Securities LLCas of 31 Dec 2025 | 4.11m | 3.26% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 4.04m | 3.20% |
| EcoR1 Capital, LLCas of 30 Sep 2025 | 3.45m | 2.73% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
